The December, 2025, approval by the US Food and Drug Administration (FDA) of hip bone mineral density as a surrogate endpoint for osteoporosis drug development marks a new era in the management of this condition, paving the way for faster and more efficient development of treatments, and providing a great alternative to fracture endpoints. Instead of waiting for endpoints such as fractures, these surrogate endpoints could substantially shorten the lifecycle of drug approval, accelerating access to new therapies.
eBioMedicine (Sun,) studied this question.